Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1980 1
1988 1
1997 2
1999 1
2000 1
2001 1
2002 2
2003 3
2004 9
2005 8
2006 8
2007 9
2008 6
2009 7
2010 10
2011 12
2012 9
2013 12
2014 16
2015 9
2016 9
2017 20
2018 14
2019 17
2020 25
2021 19
2022 15
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: . Clear all
Page 1
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.
Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V, Secker PF, Pfänder P, Loth S, Salem H, Prentzell MT, Berdel B, Iskar M, Faessler E, Reuter F, Kirst I, Kalter V, Foerster KI, Jäger E, Guevara CR, Sobeh M, Hielscher T, Poschet G, Reinhardt A, Hassel JC, Zapatka M, Hahn U, von Deimling A, Hopf C, Schlichting R, Escher BI, Burhenne J, Haefeli WE, Ishaque N, Böhme A, Schäuble S, Thedieck K, Trump S, Seiffert M, Opitz CA. Sadik A, et al. Among authors: burhenne j. Cell. 2020 Sep 3;182(5):1252-1270.e34. doi: 10.1016/j.cell.2020.07.038. Epub 2020 Aug 19. Cell. 2020. PMID: 32818467 Free article.
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H, Flórez AF, Kreth S, Brückner LM, Yildiz U, Gartlgruber M, Odoni DI, Poschet G, Garbowicz K, Shao C, Klein C, Meier J, Zeisberger P, Nadler-Holly M, Ziehm M, Paul F, Burhenne J, Bell E, Shaikhkarami M, Würth R, Stainczyk SA, Wecht EM, Kreth J, Büttner M, Ishaque N, Schlesner M, Nicke B, Stresemann C, Llamazares-Prada M, Reiling JH, Fischer M, Amit I, Selbach M, Herrmann C, Wölfl S, Henrich KO, Höfer T, Trumpp A, Westermann F. Alborzinia H, et al. Among authors: burhenne j. Nat Cancer. 2022 Apr;3(4):471-485. doi: 10.1038/s43018-022-00355-4. Epub 2022 Apr 28. Nat Cancer. 2022. PMID: 35484422 Free PMC article.
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P. Zhou X, et al. Among authors: burhenne j. Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7. Nat Cancer. 2023. PMID: 37679568 Free PMC article.
Obesity-induced CYP2E1 activity in children.
Gade C, Dalhoff K, Petersen T, Riis T, Schmeltz C, Chabanova E, Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H. Gade C, et al. Among authors: burhenne j. Br J Clin Pharmacol. 2019 Feb;85(2):458-459. doi: 10.1111/bcp.13813. Epub 2018 Dec 9. Br J Clin Pharmacol. 2019. PMID: 30537026 Free PMC article. No abstract available.
Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers.
Breithaupt MH, Krohmer E, Taylor L, Körner E, Hoppe-Tichy T, Burhenne J, Foerster KI, Dachtler M, Huber G, Venkatesh R, Eggenreich K, Czock D, Mikus G, Blank A, Haefeli WE. Breithaupt MH, et al. Among authors: burhenne j. Br J Clin Pharmacol. 2023 Aug;89(8):2458-2464. doi: 10.1111/bcp.15720. Epub 2023 Apr 1. Br J Clin Pharmacol. 2023. PMID: 36946257
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Sigaud R, Rösch L, Gatzweiler C, Benzel J, von Soosten L, Peterziel H, Selt F, Najafi S, Ayhan S, Gerloff XF, Hofmann N, Büdenbender I, Schmitt L, Foerster KI, Burhenne J, Haefeli WE, Korshunov A, Sahm F, van Tilburg CM, Jones DTW, Pfister SM, Knoerzer D, Kreider BL, Sauter M, Pajtler KW, Zuckermann M, Oehme I, Witt O, Milde T. Sigaud R, et al. Among authors: burhenne j. Neuro Oncol. 2023 Mar 14;25(3):566-579. doi: 10.1093/neuonc/noac183. Neuro Oncol. 2023. PMID: 35882450 Free PMC article.
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Hohmann N, Sprick MR, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A, Springfeld C. Hohmann N, et al. Among authors: burhenne j. Clin Transl Sci. 2023 Dec;16(12):2483-2493. doi: 10.1111/cts.13661. Epub 2023 Nov 3. Clin Transl Sci. 2023. PMID: 37920921 Free PMC article.
Correction: Bay et al. Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC3A2) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine. Int. J. Mol. Sci. 2022, 23, 3637.
Bay C, Bajraktari-Sylejmani G, Haefeli WE, Burhenne J, Weiss J, Sauter M. Bay C, et al. Among authors: burhenne j. Int J Mol Sci. 2023 Mar 6;24(5):5029. doi: 10.3390/ijms24055029. Int J Mol Sci. 2023. PMID: 36902494 Free PMC article.
233 results